Aspira Women's Health - AWH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $4.45
  • Forecasted Upside: 30.88%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.40
▼ -0.1 (-2.86%)

This chart shows the closing price for AWH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aspira Women's Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AWH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AWH

Analyst Price Target is $4.45
▲ +30.88% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Aspira Women's Health in the last 3 months. The average price target is $4.45, with a high forecast of $5.60 and a low forecast of $3.30. The average price target represents a 30.88% upside from the last price of $3.40.

This chart shows the closing price for AWH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Aspira Women's Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$3.30Low
4/1/2024Cantor FitzgeraldLower TargetNeutral ➝ Neutral$4.00 ➝ $3.30Low
9/26/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$4.00Low
8/22/2023Alliance Global PartnersInitiated CoverageBuy$5.60Low
1/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$45.00 ➝ $30.00Low
9/2/2022William BlairReiterated RatingMarket PerformLow
1/11/2022Cantor FitzgeraldReiterated RatingOverweightHigh
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
3/29/2021Truist FinancialInitiated CoverageBuy$180.00N/A
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$150.00High
10/31/2020MacquarieReiterated RatingHoldLow
10/30/2020MacquarieReiterated RatingHoldLow
10/30/2020William BlairReiterated RatingOutperformHigh
10/29/2020William BlairInitiated CoverageOutperformHigh
10/14/2020Brookline Capital ManagementReiterated RatingBuyHigh
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/26/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/26/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/25/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
2/23/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/23/2024

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Aspira Women's Health logo
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
Read More

Today's Range

Now: $3.40
Low: $3.39
High: $3.52

50 Day Range

MA: $3.67
Low: $2.64
High: $4.96

52 Week Range

Now: $3.40
Low: $2.31
High: $6.75

Volume

7,829 shs

Average Volume

25,458 shs

Market Capitalization

$41.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Aspira Women's Health?

The following Wall Street research analysts have issued research reports on Aspira Women's Health in the last year: Alliance Global Partners, Cantor Fitzgerald, and StockNews.com.
View the latest analyst ratings for AWH.

What is the current price target for Aspira Women's Health?

2 Wall Street analysts have set twelve-month price targets for Aspira Women's Health in the last year. Their average twelve-month price target is $4.45, suggesting a possible upside of 30.9%. Alliance Global Partners has the highest price target set, predicting AWH will reach $5.60 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $3.30 for Aspira Women's Health in the next year.
View the latest price targets for AWH.

What is the current consensus analyst rating for Aspira Women's Health?

Aspira Women's Health currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AWH.

What other companies compete with Aspira Women's Health?

Other companies that are similar to Aspira Women's Health include ImmuCell, ARCA biopharma, VolitionRx, OncoCyte and Cardio Diagnostics. Learn More about companies similar to Aspira Women‘s Health.

How do I contact Aspira Women's Health's investor relations team?

Aspira Women's Health's physical mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company's listed phone number is 512-519-0400 and its investor relations email address is [email protected]. The official website for Aspira Women's Health is www.aspirawh.com. Learn More about contacing Aspira Women‘s Health investor relations.